Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

The Trend of Immunotherapy Combined with Nanomedicine

Author(s): Shigao Huang* and Qi Zhao

Volume 29, Issue 22, 2022

Published on: 18 January, 2022

Page: [3817 - 3818] Pages: 2

DOI: 10.2174/0929867328666211117094947

« Previous Next »
[1]
Huang, S.; Dang, Y.; Li, F.; Wei, W.; Ma, Y.; Qiao, S.; Wang, Q. Biological intensity modulated radiotherapy plus neoadjuvant chemotherapy for peritoneum multiple metastasis of ovarian cancer: a case report. Oncol. Lett., 2015, 9(3), 1239-1243.
[http://dx.doi.org/10.3892/ol.2014.2820] [PMID: 25663890]
[2]
Huang, S.; Fong, C.I.; Xu, M.; Han, B.; Yuan, Z.; Zhao, Q. Nano-loaded natural killer cells as carriers of ICG for synergetic cancer immunotherapy and phototherapy. J. Innov. Opt. Health Sci., 2019, 12(03)1941002
[http://dx.doi.org/10.1142/S1793545819410025]
[3]
Gao, H.X.; Huang, S.G.; Du, J.F.; Zhang, X.C.; Jiang, N.; Kang, W.X.; Mao, J.; Zhao, Q. Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery. Int. J. Biol. Sci., 2018, 14(14), 2065-2072.
[http://dx.doi.org/10.7150/ijbs.28608] [PMID: 30585269]
[4]
Dang, Y.Z.; Li, X.; Ma, Y.X.; Li, X.L.; Yang, T.; Lu, W.L.; Huang, S.G. 18F-FDG-PET/CT-guided intensity-modulated radiotherapy for 42 FIGO III/IV ovarian cancer: a retrospective study. Oncol. Lett., 2019, 17(1), 149-158.
[http://dx.doi.org/10.3892/ol.2018.9601] [PMID: 30655750]
[5]
Dang, Y-Z.; Zhang, D-X.; Wang, G-D.; Zhao, H-L.; Huang, S-G.; Li, J. Safety and Efficacy of the Metabolic Profiling of the BIMRT Utilizing 18F FDG PET-CT. Technol. Cancer Res. Treat., 2020, 19, 1533033820960723.
[http://dx.doi.org/10.1177/1533033820960723] [PMID: 32990157]
[6]
Ayoub, N.M.; Al-Shami, K.M.; Yaghan, R.J. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer (Dove Med. Press), 2019, 11, 53-69.
[http://dx.doi.org/10.2147/BCTT.S175360] [PMID: 30697064]
[7]
El Chaer, F.; Holtzman, N.G.; Sausville, E.A.; Law, J.Y.; Lee, S.T.; Duong, V.H.; Baer, M.R.; Koka, R.; Singh, Z.N.; Hardy, N.M.; Emadi, A. Relapsed philadelphia chromosome-positive pre-B-ALL after CD19-directed CAR-T cell therapy successfully treated with combination of blinatumomab and ponatinib. Acta Haematol., 2019, 141(2), 107-110.
[http://dx.doi.org/10.1159/000495558] [PMID: 30695783]
[8]
Sambi, M.; Bagheri, L.; Szewczuk, M.R. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J. Oncol., 2019, 2019, 4508794-4508794.
[http://dx.doi.org/10.1155/2019/4508794] [PMID: 30941175]
[9]
Bolm, L.; Käsmann, L.; Paysen, A.; Karapetis, C.; Rades, D.; Wellner, U.F.; Keck, T.; Watson, D.I.; Hummel, R.; Hussey, D.J. Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer. Anticancer Res., 2018, 38(6), 3231-3242.
[http://dx.doi.org/10.21873/anticanres.12588] [PMID: 29848670]
[10]
Huang, S.; Zhao, Q. Nanomedicine-combined immunotherapy for cancer. Curr. Med. Chem., 2020, 27(34), 5716-5729.
[http://dx.doi.org/10.2174/0929867326666190618161610] [PMID: 31250752]
[11]
Lakshmanan, V-K.; Jindal, S.; Packirisamy, G.; Ojha, S.; Lian, S.; Kaushik, A.; Alzarooni, A.I.M.A.; Metwally, Y.A.F.; Thyagarajan, S.P.; Do Jung, Y.; Chouaib, S. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. Cancer Gene Ther., 2021, 28(9), 911-923.
[http://dx.doi.org/10.1038/s41417-021-00299-4] [PMID: 33558704]

Rights & Permissions Print Cite
Article Metrics
7
1
© 2024 Bentham Science Publishers | Privacy Policy